1 |
Biologic dmard |
- |
- |
- |
- |
046 [2] 46, 271 💬 |
2 |
Biological dmards |
- |
- |
- |
- |
086 [1] 86 💬 |
3 |
Classic dmards treatment group |
- |
- |
- |
- |
046 [1] 46 💬 |
4 |
Co-medication: synthetic dmards |
- |
- |
- |
- |
046 [1] 46 💬 |
5 |
Conventional dmard combination |
- |
- |
- |
- |
046 [1] 46 💬 |
6 |
Conventional dmards |
- |
- |
- |
- |
046 [1] 46 💬 |
7 |
Conventional synthetic dmard |
- |
- |
- |
- |
046 [1] 46 💬 |
8 |
Disease-modifying antirheumatic drugs (dmards) |
- |
- |
- |
- |
046 [1] 46 💬 |
9 |
Dmard |
- |
- |
- |
- |
046 [1] 46 💬 |
10 |
Dmard cessation |
- |
- |
- |
- |
046 [1] 46 💬 |
11 |
Dmard maintenance |
- |
- |
- |
- |
046 [1] 46 💬 |
12 |
Dmard therapy |
- |
- |
- |
- |
046 [1] 46 💬 |
13 |
Dmards |
- |
- |
- |
- |
046 [2] 46, 271 💬 |
14 |
Dmards (disease-modifying antirheumatic drugs) |
- |
- |
- |
- |
046 [1] 46 💬 |
15 |
Dmards (methotrexate |
Methotrexate |
[2] D00142 D00142, D02115 D02115 💬 |
DHFR [2] DHFR, DHFR2 💬 |
Antifolate resistance [5] Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate |
046 [1] 46 💬 |
16 |
Dmards or biologics |
- |
- |
- |
- |
046 [1] 46 💬 |
17 |
Etanercept, other biologics, disease-modifying antirheumatic drugs (dmards), etc |
Etanercept |
[1] D00742 D00742 💬 |
LTA [2] LTA, TNF 💬 |
AGE-RAGE signaling pathway in diabetic complications [65] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
046 [1] 46 💬 |
18 |
Huc-msc + dmards |
- |
- |
- |
- |
046 [1] 46 💬 |
19 |
Non-biologic disease modifying anti-rheumatic drug (dmard) |
- |
- |
- |
- |
046 [1] 46 💬 |
20 |
Non-biologic dmards |
- |
- |
- |
- |
046 [2] 46, 86 💬 |
21 |
Non-biological dmard's |
- |
- |
- |
- |
046 [1] 46 💬 |
22 |
Non-biological dmards |
- |
- |
- |
- |
046 [1] 46 💬 |
23 |
Nonbiologic dmards of investigator's choice |
- |
- |
- |
- |
046 [1] 46 💬 |
24 |
Other dmards |
- |
- |
- |
- |
046 [1] 46 💬 |
25 |
Other: group 2 (dmards treated group) |
- |
- |
- |
- |
046 [1] 46 💬 |
26 |
Patient treated with dmard |
- |
- |
- |
- |
046 [1] 46 💬 |
27 |
Permitted dmards |
- |
- |
- |
- |
046 [1] 46 💬 |
28 |
Phase 1: conventiaonal dmard |
- |
- |
- |
- |
046 [1] 46 💬 |
29 |
Rheumatoid arthritis with disease-modifying drugs (dmards) |
- |
- |
- |
- |
046 [1] 46 💬 |
30 |
Standard dmards (disease modifying anti rheumatic drugs) |
- |
- |
- |
- |
046 [1] 46 💬 |
31 |
Synthetic dmard(s) |
- |
- |
- |
- |
046 [1] 46 💬 |
32 |
Therapy with disease-modifying anti rheumatic drugs (dmard) |
- |
- |
- |
- |
046 [1] 46 💬 |
33 |
Tnf-a antagonists, non-tnfs, dmard non-biologics |
- |
- |
- |
- |
046 [2] 46, 271 💬 |
34 |
Uc-msc+dmards |
- |
- |
- |
- |
046 [1] 46 💬 |